Neuralstem rises after announcing start of stem cell trial

|By:, SA News Editor

The University of Michigan has treated the first two patients in a Phase II trial testing the effectiveness of Neuralstem's (CUR +5.9%) NSI-566 neural stem cells in treating ALS (Lou Gehrig's disease). (PR)

The trial is meant to treat 15 patients through a maximum of 40 injections. Today's news comes a month after Neuralstem announced Emory University, which is also taking part in the Phase II trial, had treated its first trial patient.